跳到主要内容

NVRA

NASDAQ

Novara Biotech

Healthcare · Biotechnology

Updated UTC

US$410.77

+5.46+1.35%

After hoursUS$412.82+0.50%

350.00400.0005/2106/2608/0309/0710/1311/18410.77

130 candlesRange +20.09%

Key statistics

Open
US$405.06
High
US$411.55
Low
US$402.66
Previous close
US$405.31
成交量
380.7万
Average volume
314.31万
市值
3936.49亿
P/E ratio
37.55
EPS
US$10.94
Dividend yield
—
52-week high
US$412.94
52-week low
US$295.67

Financial statements

Units: USD · Annual
ItemFY2022FY2023FY2024FY2025FY2026
Revenue316.69亿372.61亿419.58亿483.11亿536.73亿
Gross profit187.6亿215.28亿238.96亿264.59亿323.39亿
Operating income62.56亿76.2亿78.45亿95.81亿117.16亿
Net income48.83亿56.3亿61.71亿57.75亿76.46亿

About the company

Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.

Related news

Demo
  • Novara Biotech reports quarterly revenue above the internal plan

    Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.

    Sector Desk

  • Novara Biotech expands manufacturing capacity in Cambridge

    The company approved a multi-year capital program intended to shorten lead times for its largest customers.

    Sector Desk

  • Analyst note trims Novara Biotech price target on valuation

    A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.

    Sector Desk

  • Novara Biotech appoints new chief financial officer

    The board named an internal candidate with prior treasury and investor-relations experience to the role.

    Sector Desk

  • Novara Biotech announces share repurchase authorization

    The authorization covers a modest slice of the float and will be funded from operating cash flow.

    Terminal Brief